Sign In
Buy LOGC
$9.02
-0.300 (-3.22%)
At Close: Jun 22, 2026
LEXINGTON, Mass., June 2, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare
LogicBio Therapeutics to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 01'st Jun 2021
LEXINGTON, Mass., June 1, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rar
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments
07:00am, Wednesday, 19'th May 2021
LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare
LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update
07:30am, Monday, 10'th May 2021
LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical-stage genetic medicine company pioneering gene delivery and gene editing
LogicBio Therapeutics Strengthens Management Team with Key Appointments
07:05am, Monday, 10'th May 2021
LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
05:29pm, Monday, 03'rd May 2021
CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will co
